Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis

Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis

Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) provide clinical benefits over chemotherapy for lung cancer patients with EGFR activating mutations. Despite initial clinical responses, long‐term efficacy is not possible because of acquired resistance to these thera...

Full description

Bibliographic Details
Main Authors: Mark C. Howell, Ryan Green, Roukiah Khalil, Elspeth Foran, Waise Quarni, Rajesh Nair, Stanley Stevens, Aleksandr Grinchuk, Andrew Hanna, Shyam Mohapatra, Subhra Mohapatra
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:FASEB BioAdvances
Subjects:
cholesterol
drug tolerance
EGFR TKIs
lung cancer
Online Access:https://doi.org/10.1096/fba.2019-00081

Internet

https://doi.org/10.1096/fba.2019-00081

Similar Items